TD Cowen Boosts Twist Bioscience (NASDAQ:TWST) Price Target to $43.00

Twist Bioscience (NASDAQ:TWST) had its price objective upped by equities research analysts at TD Cowen from $32.00 to $43.00 in a research note issued on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. TD Cowen’s price objective would suggest a potential upside of 22.25% from the stock’s current price.

Several other equities research analysts have also recently weighed in on TWST. Cowen restated a “buy” rating on shares of Twist Bioscience in a research note on Thursday. Evercore ISI restated an “outperform” rating and set a $42.00 price objective on shares of Twist Bioscience in a research report on Monday. Stephens assumed coverage on shares of Twist Bioscience in a research report on Monday, November 3rd. They issued an “overweight” rating and a $41.00 target price on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Twist Bioscience in a research report on Monday, December 29th. Finally, Barclays raised their price objective on Twist Bioscience from $37.00 to $39.00 and gave the stock an “overweight” rating in a report on Monday, December 15th. Nine research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $44.67.

Twist Bioscience Stock Down 3.8%

Shares of NASDAQ TWST traded down $1.38 during midday trading on Thursday, hitting $35.17. The company’s stock had a trading volume of 647,352 shares, compared to its average volume of 1,277,513. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.64 and a quick ratio of 3.33. The firm has a market capitalization of $2.15 billion, a price-to-earnings ratio of -26.76 and a beta of 2.19. The business’s fifty day simple moving average is $31.37 and its two-hundred day simple moving average is $31.15. Twist Bioscience has a 1 year low of $23.30 and a 1 year high of $55.33.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings results on Friday, November 14th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($0.05). Twist Bioscience had a negative return on equity of 27.40% and a negative net margin of 20.63%.The company had revenue of $99.01 million for the quarter, compared to analysts’ expectations of $97.40 million. On average, equities analysts predict that Twist Bioscience will post -2.12 EPS for the current year.

Insider Buying and Selling at Twist Bioscience

In other Twist Bioscience news, insider Dennis Cho sold 1,019 shares of Twist Bioscience stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $32.08, for a total transaction of $32,689.52. Following the transaction, the insider owned 120,694 shares of the company’s stock, valued at $3,871,863.52. The trade was a 0.84% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Paula Green sold 1,084 shares of the business’s stock in a transaction dated Monday, November 3rd. The shares were sold at an average price of $32.08, for a total value of $34,774.72. Following the completion of the transaction, the senior vice president owned 142,187 shares in the company, valued at $4,561,358.96. This trade represents a 0.76% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 60,699 shares of company stock worth $1,919,823. 3.01% of the stock is owned by insiders.

Institutional Trading of Twist Bioscience

Several hedge funds have recently added to or reduced their stakes in TWST. EdgePoint Investment Group Inc. raised its holdings in Twist Bioscience by 71.1% in the 3rd quarter. EdgePoint Investment Group Inc. now owns 4,082,319 shares of the company’s stock valued at $114,876,000 after acquiring an additional 1,696,377 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Twist Bioscience by 186.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,442,262 shares of the company’s stock valued at $95,883,000 after acquiring an additional 1,588,587 shares during the period. Artisan Partners Limited Partnership raised its position in Twist Bioscience by 26.7% in the third quarter. Artisan Partners Limited Partnership now owns 6,410,900 shares of the company’s stock worth $180,403,000 after purchasing an additional 1,349,867 shares in the last quarter. Millennium Management LLC lifted its stake in Twist Bioscience by 151.5% during the third quarter. Millennium Management LLC now owns 1,793,850 shares of the company’s stock worth $50,479,000 after purchasing an additional 1,080,722 shares during the period. Finally, Balyasny Asset Management L.P. grew its stake in shares of Twist Bioscience by 934.0% in the 2nd quarter. Balyasny Asset Management L.P. now owns 628,241 shares of the company’s stock valued at $23,113,000 after purchasing an additional 567,481 shares during the period.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.